PulseSight presents PST-611 Phase I new early clinical efficacy data at EURETINA, offering a potential breakthrough approach to treat Dry AMD/Geographic Atrophy

Phase 1positivePST-611Positive

AI Analysis

Summary

PulseSight Therapeutics presented early Phase 1 clinical efficacy data for PST-611, a non-viral gene therapy for dry AMD/geographic atrophy, at the EURETINA 2026 congress in Vienna. The presentation demonstrates initial positive clinical results for the company's minimally invasive vectorized gene therapy approach.

Clinical Trial Data

Phase

Phase 1

Outcome Details

Early clinical efficacy data presented

Importance:6/10

Sentiment:

0.70

ophthalmologygene therapydry AMDgeographic atrophynon-viral vectorsminimally invasive

Read the original article

Published by GlobeNewswire Clinical Studies on October 7, 2026 7:00 AM

Read Original